Assessment of left ventricular size and function
| Parameter | MCM−;RbL/L;p130+/+ | MCM+;RbL/L;p130+/+ | MCM−;RbL/L;p130−/− | MCM+;RbL/L;p130−/− |
| TAM | + | + | + | + |
| HR (bpm) | 477 ± 6 | 473 ± 14 | 475 ± 16 | 480 ± 12 |
| EF (%) | 56.13 ± 2.02 | 50.40 ± 2.65 | 56.39 ± 3.32 | 33.52 ± 2.81a |
| FS (%) | 28.88 ± 1.29 | 25.32 ± 1.59 | 29.13 ± 2.31 | 15.97 ± 1.50a |
| LVID;d (mm) | 3.87 ± 0.07 | 3.98 ± 0.15 | 3.76 ± 0.02 | 4.78 ± 0.28a |
| LVID;s (mm) | 2.74 ± 0.08 | 2.98 ± 0.16 | 2.67 ± 0.08 | 4.02 ± 0.28a |
| LVPW;d (mm) | 0.63 ± 0.03 | 0.65 ± 0.14 | 0.67 ± 0.02 | 0.78 ± 0.03a |
| LVPW;s (mm) | 0.89 ± 0.02 | 0.89 ± 0.03 | 0.89 ± 0.02 | 0.78 ± 0.03a |
| Parameter | MCM−;RbL/L;p130+/+ | MCM+;RbL/L;p130+/+ | MCM−;RbL/L;p130−/− | MCM+;RbL/L;p130−/− |
| TAM | + | + | + | + |
| HR (bpm) | 477 ± 6 | 473 ± 14 | 475 ± 16 | 480 ± 12 |
| EF (%) | 56.13 ± 2.02 | 50.40 ± 2.65 | 56.39 ± 3.32 | 33.52 ± 2.81a |
| FS (%) | 28.88 ± 1.29 | 25.32 ± 1.59 | 29.13 ± 2.31 | 15.97 ± 1.50a |
| LVID;d (mm) | 3.87 ± 0.07 | 3.98 ± 0.15 | 3.76 ± 0.02 | 4.78 ± 0.28a |
| LVID;s (mm) | 2.74 ± 0.08 | 2.98 ± 0.16 | 2.67 ± 0.08 | 4.02 ± 0.28a |
| LVPW;d (mm) | 0.63 ± 0.03 | 0.65 ± 0.14 | 0.67 ± 0.02 | 0.78 ± 0.03a |
| LVPW;s (mm) | 0.89 ± 0.02 | 0.89 ± 0.03 | 0.89 ± 0.02 | 0.78 ± 0.03a |
2D echocardiographic analysis of left ventricle function in mice with the indicated genotypes 4 wk after TAM treatment. n = 5 mice per group. Results are presented as the mean ± SEM. HR, heart rate; EF, ejection fraction; FS, fractional shortening; LVID;d/s, left ventricular internal dimension in diastole/systole; LVPW;d/s, left ventricular posterior wall thickness in diastole/systole.
P < 0.05 by analysis of variance for MCM−;RbL/L;p130+/+, MCM+;RbL/L;p130+/+, and MCM−;RbL/L;p130−/− versus MCM+;RbL/L;p130−/− littermates.